Trust me there are buyers of ALNY that are propping it. This goes back a long ways. I can't go into things here, it will play out though. If ALNY loses the TTR amyloidosis battle they are going into a huge dry spell without any products up for approval for at least another two years. The TT's of this world follow and worship their CEO, and the CEO is a genius in propaganda. He just bought 7500 shares of the stock.....Let me see, I sell $9 million dollars worth of stock and my shares come under pressure and I thus buy 7500 shares and talk another insider into buying shares...though he did buy a lot more than the CEO and now I have a further prop. The bragging of a semi-annual dosing, or even quarterly without an antidote is nuts. How would you like to receive a shot with 6 months duration and develop an allergic reaction shortly thereafter and have six months of putting up with something bad and/or unknown. And what effect will this kind of long-acting drug have on the biomarker BACE-1. If you have chance contact me at IV. I can answer questions better over there. t
More conviction that ALNY has a platform problem. IONS is really IMO ahead on both fronts for the TTR-amyloidosis patients. Think about it, if ALNY loses these two battles when or how long will it take for another drug if theirs to be up for possible approval. The AAT drug that they dropped earlier IONS had dropped theirs when they realized that alpha-one anti-trypinase is made in other organs than just the liver. Thus the copy-cat strategy back fired on JM. t
I honestly don't think so. IMO JM from ALNY attacked IONS saying they have a platform problem.....and maybe they do at high doses, only God knows for sure. But he knew for sure was that ALNY definitely had a platform problem or problems with their Gal-Vac technology. With IONS combo of 2.5 generation and their LUCA form of their technology they have a 300 fold increase in potency and they can use their drugs in organs outside of the liver. A very important drug read out will be their Myotonic Dystrophy Tyoe 1 drug that uses both of those technologies. t
MiniCC with WW:
I'm going to do this on lunch break. I called WW to get some background on the issues that seem to be plaguing us:
1)First I ask him about this Jefferies report that came out this am. I pointed out that it seemed to me that IONS was being set up again for an "AEGR-like experience" and I went through the same issues that I posted earlier in this regard.
He noted that those two Jefferies analysts didn't know too much and that they have very unscientific information. He also noted that their information gathering was very suspect and it was on par with propaganda. He brought out the issue of how you ask a question and how that would direct your answer. And then how people could report their "info" from their "study." He noted that from his info when patient's parents are asked, "Would you like your child to receive an FDA approved drug for SMA or a genetic trial drug?" that their data showed a very heavy skewing of parents wanting their child to be taking the approved drug. He noted that if the question was asked devoid of the issue of an approved drug, and simply asked "would you like your child to try a new genetic drug in trials" for their child's SMA that the results would show a positive yes for the genetic drug wanting to be used. I asked him that with his exposure to BIIB were they highly committed to lauching this drug and really getting it out there? He noted most definitely. I ask if there was ANY chance that there would be a shortage of drug once it has been approved, or some type of possible logistical problem getting people on the drug. He noted that the DEFINITELY had more than enoough drug to meet demand and more as it stands now. There was no concern on IONS part in this regard. He reminded me that it is only a 12 mg dosing. He notes that they "have plenty of drug supply for the launching and thereafter" and this would definitely not be a problem. He further pointed out they witnessed BIIB going through every detail to the nth degree BIIB to get this drug out as quickly and as widely as possible....IONS was convinced of that(bodes well for further deals then IMO).
2)I asked again about a partner's preparedness when I went after GSK as a partner. I asked if he or people at IONS had witnessed GSK's committment to the TTR-amyloidosis drug? He noted "most definitely." I plugged after that and ask if GSK was keenly aware of what ALNY was saying and how they were conducting themselves in regards to preparation and aggressive launch of their own TTR-amyloidosis version of their drug after being approved. He noted that GSK had plenty of contacts and that IONS was constantly keeping them informed as well. He noted that GSK had a very great interst in getting this drug out and to market and he noted again about a 4 month head start on ALNY's drug. He also noted that the door was open for cardiac indication once they get data on the FAP portion of their study.
3)I asked him if there was any way that Castle would be also co-promoting the Akcea drugs? He noted "no" and that he felt that they at IONS were planning on waiting for a big pharma partner almost for sure when their indications for the drugs are able to be expanded to larger populations.
4)Asked about the Factor XI inhibitor and Bayer. He noted that there are as we already knew, three contenders with Bayer for the Factor XI inhibitor space. The IONS drug itself has been moving forward and he noted no trepidations or anticipated problems but that we would just have to wait and see how things go. At this time there is no moth-balling of the drug. He did note that Bayer also was very committed to studying the drugs prospects and hopeful for being able to us it.
I had several other questions but once I reach the 5 to 7 minute mark I want to let him go so as to not make where he doesn't want to return my calls in the future. t
They got $3 million yesterday from a CF foundation and they got notification today of a rapid review in Europe for their SMA drug. This is a great board now BTW. t
If you really believe in their deep-seated technology you don't want to see them bought out. They should be able to to in about $600 million a year within three to five years with their SMA drug. Look for news about their Type 2 and Type 3 data to come out before Sept 15th. Couple that with probably another $400 million for the two Akcea indications for their ApoC III inhibitor, add in another $400 for their Lp(a) inhibitor, and at least $600 million from their TTR amyloidosis inhibitor and you have $2,000,000,000 divided by 135,000,000 time 30 and you have about 444 per share and I don't think that is a stretch at all and we havev't even talked about the other 34 drugs in the pipeline. Wall Street will catch on fast once they realize the prime time use or INOS SMA drug. t
Look for approval of IONS SMA drug in both the US and the EU very soon. Also, there is really nothing to treat really high level of triglycerides. With IONS ApoC III inhibitor look for an approval of that drug for the two orphan indications. For a bigger populations for just elevated triglycerides that will take time. But within three years IONS should be grossing over a billion a year. By that time their 2.5 generation LICA form Lp(a) drug could also very well be approved. IMO by then the company should be given a P/E of at least 30. t
This is kind of a cool set up as long as Y keeps it going. Skybusted lost huge on PTLA and they got an FDA letter and no approval. Things will really start flying for IONS over the next 12 months. t
I can only get to this message board using my iPhone, but that is better than nothing and top shelf might ever find out about it. 😆